Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (552)	8/3/2006 1:08:11 PM
From: Jibacoa	Respond to of 802

Introgen Therapeutics, Inc. to Present at Canaccord Adams' 26th Annual Summer Seminar Thursday August 3, 12:00 pm ET AUSTIN, Texas, Aug. 3 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN - News) announced today that it will deliver a presentation at the 26th Annual Canaccord Adams Summer Seminar in Boston. Dr. Robert E. Sobol, Introgen's senior vice president of Medical and Scientific Affairs, is scheduled to present to leading institutional investment representatives on Tuesday, August 8, 2006, at the Boston Marriott Long Wharf Hotel. Dr. Sobol will join executives from nearly 200 public and private companies for the Summer Seminar, one of the longest-running institutional events focused exclusively on growth companies. Introgen's presentation will be web cast live and can be accessed at: corporate-ir.net Also participating at the conference is Max W. Talbott, Introgen's senior vice president of Worldwide Commercial Development. Dr. Talbott will participate in a panel discussion about Accelerated Approvals for Oncology Drugs. The panel will be held on Tuesday, August 8 from 12:00 -12:55 p.m. ET. "We look forward to showcasing our company to some of the country's top growth investors at this year's Summer Seminar," said David G. Nance, President and CEO of Introgen. "This is an ideal venue in which we can provide an important mid-year update of our growth strategy and achievements." "This year's conference marks an important occasion since our new global platform allows us to substantially expand the scope of the event," said Kevin Dunn, President and CEO of Canaccord Adams Inc. "The Summer Seminar strives to be a top-quality event for institutional clients and venture capitalists, connecting them with excellent growth industries while also giving corporate clients access to investing insights and valuable information. Our goal is providing a premier forum for information flow and networking for public and private growth companies, venture capitalists and institutional investors." The Canaccord Adams Annual Summer Seminar is one of the oldest and largest programs showcasing both publicly traded and privately held growth companies. Most of the presenting public companies are covered by Canaccord Adams' global team of equity analysts. To learn more about the conference, please contact Nadine Miller at 617.371.3842 or Nadine.Miller@CanaccordAdams.com . Snip Bernard